AMYLOID CARDIOMYOPATHY, TRANSTHYRETIN-RELATED

Clinical trials for AMYLOID CARDIOMYOPATHY, TRANSTHYRETIN-RELATED explained in plain language.

Never miss a new study

Get alerted when new AMYLOID CARDIOMYOPATHY, TRANSTHYRETIN-RELATED trials appear

Sign up with your email to follow new studies for AMYLOID CARDIOMYOPATHY, TRANSTHYRETIN-RELATED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1 Completed 1

Heart disease patients get chance for extended treatment in safety Follow-Up

Disease control Ongoing

This study aims to monitor the long-term safety of the drug acoramidis for people with a serious heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It is open to 389 participants who successfully completed a prior 30-month clinical trial of the same drug. The …

Matched conditions: AMYLOID CARDIOMYOPATHY, TRANSTHYRETIN-RELATED

Phase: PHASE3 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Disease control

Last updated Mar 30, 2026 14:34 UTC

AMYLOID CARDIOMYOPATHY, TRANSTHYRETIN-RELATED

Get alerted when new AMYLOID CARDIOMYOPATHY, TRANSTHYRETIN-RELATED trials appear

Heart disease patients get chance for extended treatment in safety Follow-Up